BYOL COMBI

This brand name is authorized in Croatia

Active ingredients

The drug BYOL COMBI contains a combination of these active pharmaceutical ingredients (APIs):

1 Ramipril
UNII L35JN3I7SJ - RAMIPRIL

Ramiprilat, the active metabolite of the prodrug ramipril, inhibits the enzyme dipeptidylcarboxypeptidase I (synonyms: angiotensin-converting enzyme; kininase II). In plasma and tissue this enzyme catalyses the conversion of angiotensin I to the active vasoconstrictor substance angiotensin II, as well as the breakdown of the active vasodilator bradykinin. Reduced angiotensin II formation and inhibition of bradykinin breakdown lead to vasodilatation.

Read about Ramipril
2 Bisoprolol
UNII UR59KN573L - BISOPROLOL FUMARATE

Bisoprolol is a potent highly beta1-selective-adrenoceptor blocking agent, lacking intrinsic stimulating and without relevant membrane stabilising activity.

Read about Bisoprolol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C09BX05 C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09B ACE inhibitors, combinations → C09BX ACE inhibitors, other combinations
Discover more medicines within C09BX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: HR Agencija za lijekove i medicinske proizvode Identifier(s): HR-H-265900355, HR-H-355894664, HR-H-459290443, HR-H-495084169, HR-H-785874468, HR-H-804824400

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.